At Dr. David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments. But recently, another word is coming up just as often — generics. "It is a ...
Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...
In a shot in the arm for India’s high-growth weight-loss medicines market, generic versions of Danish drugmaker Novo Nordisk’s blockbuster drug semaglutide will hit the shelves on Saturday, with price ...
The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...
To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...
Priyanka Chigurupati is overseeing a strategic shift at Granules India Ltd, moving the company from its traditional role as a high-volume Active Pharmaceutical Ingredient (API) supplier towards one ...
The FDA has approved a generic version of fluticasone propionate (marketed as Flovent HFA), according to a statement issued on March 3. The approval extends the accessibility of the medication, ...
Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...
Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results